Mrs Mandy Hall, MS | |
216 14th Ave Sw, Sidney, MT 59270-3519 | |
(406) 488-2166 | |
Not Available |
Full Name | Mrs Mandy Hall |
---|---|
Gender | Female |
Speciality | Student In An Organized Health Care Education/training Program |
Location | 216 14th Ave Sw, Sidney, Montana |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1043774656 | NPI | - | NPPES |
Mailing Address | Practice Location Address |
---|---|
Mrs Mandy Hall, MS 1399 14th St Sw, Sidney, MT 59270-5411 Ph: (406) 973-4256 | Mrs Mandy Hall, MS 216 14th Ave Sw, Sidney, MT 59270-3519 Ph: (406) 488-2166 |
News Archive
A modified version of the Clostridium novyi (C. novyi-NT) bacterium can produce a strong and precisely targeted anti-tumor response in rats, dogs and now humans, according to a new report from Johns Hopkins Kimmel Cancer Center researchers.
A new therapy under development for the treatment of irritable bowel syndrome with diarrhea predominance appears to provide significant improvements in measures of quality of life, according to a study presented at the 69th Annual Meeting of the American College of Gastroenterology.
Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestations of chronic Graft-versus-Host disease.
Currently, no definitive standard of care exists for adolescent and young adults (AYA) with acute lymphoblastic leukemia (ALL). Recent research suggests that AYAs treated with pediatric treatment protocols have better outcomes than those treated with adult treatment protocols.
People with certain forms of early-onset Parkinson's disease could potentially benefit from taking a medication used to treat certain forms of cancer, according to new research by University of Leicester scientists and funded by the Medical Research Council.
› Verified 6 days ago